-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang Fourth Pharmaceutical Obtains Drug Production Registration Approval for Cefdinir Capsules
Category:
Time：2020-07-20
Recently, Shijiazhuang No.4 Pharmaceutical Co., Ltd. obtained the drug registration certificate for cefdinir capsules (0.1g) approved by the National Medical Products Administration.
Recently, Shijiazhuang No.4 Pharmaceutical Co., Ltd. obtained the drug registration certificate for cefdinir capsules (0.1g) approved by the National Medical Products Administration.
The cefdinir capsules (0.1g) approved by Shijiazhuang Fourth Pharmaceutical were submitted under Category 4 of the chemical drug registration classification and, upon approval, are deemed to have passed the consistency evaluation. Shijiazhuang Fourth Pharmaceutical is one of only three domestic companies that have already passed the consistency evaluation for this product.
It is reported that cefdinir is a cephalosporin antibiotic primarily used to treat various infections caused by strains sensitive to cefdinir, including those from the genera Staphylococcus, Streptococcus, Streptococcus pneumoniae, Peptostreptococcus, Propionibacterium, Neisseria gonorrhoeae, Moraxella catarrhalis, Escherichia coli, Klebsiella species, Proteus mirabilis, Providencia species, and Haemophilus influenzae—such as pharyngitis, tonsillitis, and acute bronchitis.
According to data from Meinian Network, in recent years the market for cefdinir at the terminal level—comprising urban public hospitals, county-level public hospitals, urban community health centers, and township health clinics—in China’s public medical institutions has been expanding steadily. In 2019, sales revenue reached 3.196 billion yuan, representing a year-on-year increase of 7.54%. Currently, the main dosage forms of cefdinir available on the market include tablets, dispersible tablets, and capsules, with capsules accounting for 48.28% of the market share.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license